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Trigeminal neuralgia
New classification and diagnostic grading for practice and research
ABSTRACT
Trigeminal neuralgia (TN) is an exemplary condition of neuropathic facial pain. However, formally
classifying TN as neuropathic pain based on the grading system of the International Association
for the Study of Pain is complicated by the requirement of objective signs confirming an underly-
ing lesion or disease of the somatosensory system. The latest version of the International Classi-
fication of Headache Disorders created similar difficulties by abandoning the term symptomatic
TN for manifestations caused by major neurologic disease, such as tumors or multiple sclerosis.
These diagnostic challenges hinder the triage of TN patients for therapy and clinical trials,
and hamper the design of treatment guidelines. In response to these shortcomings, we have
developed a classification of TN that aligns with the nosology of other neurologic disorders and
neuropathic pain. We propose 3 diagnostic categories. Classical TN requires demonstration of
morphologic changes in the trigeminal nerve root from vascular compression. Secondary TN is
due to an identifiable underlying neurologic disease. TN of unknown etiology is labeled idiopathic.
Diagnostic certainty is graded possible when pain paroxysms occur in the distribution of the tri-
geminal nerve branches. Triggered paroxysms permit the designation of clinically established TN
and probable neuropathic pain. Imaging and neurophysiologic tests that establish the etiology of
classical or secondary TN determine definite neuropathic pain. Neurology® 2016;87:220–228
GLOSSARY
DTI 5 diffusion tensor imaging; ICHD 5 International Classification of Headache Disorders; MS 5 multiple sclerosis; TN 5
trigeminal neuralgia.
The diagnosis of trigeminal neuralgia (TN) critically depends on a patient’s description of
pathognomonic pain attacks.1 Unequivocal definition of the characteristic features of TN is
therefore mandatory. Diagnostic criteria must encompass variants of the clinical phenotype and
incorporate the etiology of TN. However, existing criteria are plagued by terminologic incon-
sistencies that compromise the communication among patients, physicians, and researchers
(appendix e-1 on theNeurology®Web site at Neurology.org). Two recently published diagnostic
guidelines have inadvertently made the classification of TN harder.2,3
Although TN is a prototype of neuropathic pain, typical TN does not fit the grading system
for the diagnosis of neuropathic pain. For a definite diagnosis, the grading system requires objec-
tive signs or tests that reveal an underlying lesion or disease of the nervous system.2 This
requirement is suitable for secondary forms of TN, but cannot be applied to classical TN,
the most common form of the neuralgia.4,5 Conversely, the most recent edition of the Inter-
national Classification of Headache Disorders (ICHD) no longer lists symptomatic or secondary
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TN as a diagnostic category,3 leaving a widely
used designation for TN that is caused by
a major neurologic disease without defined
criteria. Recognizing these shortcomings, we
developed a new classification of TN that ac-
commodates the needs of clinical practice
and research, matches the grading system for
neuropathic pain, and corresponds to the
common nosology of neurologic disorders.
Treatment recommendations are beyond the
scope of this article, but we anticipate that they
will become more specific following wide-
spread use of the proposed classification.
METHODS With endorsements from the Neuropathic Pain
Special Interest Group of the International Association for the
Study of Pain and the Scientific Panel Pain of the European Acad-
emy of Neurology, we convened experts in TN, diagnostic
grading, and evidence-based medicine to review existing
definitions of TN and develop a new classification and grading
system for TN that fits the specific pathophysiology of the
disease. The authors represented multiple specialties: neurology,
neurosurgery, orofacial pain medicine, clinical pain research,
and basic neuroscience. The proposed classification of TN was
based on a thorough review of the literature and discussion
among the authors (details can be found in appendix e-2).
To align categories of TN with the grading of diagnostic cer-
tainty that was introduced for neuropathic pain,2 we first defined
criteria of possible, clinically, and etiologically established TN.
DIAGNOSTIC GRADING SYSTEM FOR TN Possible
TN. The minimum requirements for possible TN are
pain distribution within the facial or intraoral terri-
tory of the trigeminal nerve and a paroxysmal charac-
ter of pain (figure 1). The examining physician must
ascertain that the pain does not extend to the poste-
rior third of the scalp, the back of the ear, or the angle
of the mandible, as these territories are innervated by
cervical nerves (figure 2). The territory of the man-
dibular division of the trigeminal nerve reaches to the
cranium; a patient with TN in the mandibular branch
of the trigeminal nerve may therefore describe pain
both in the lower lip and the temple. If the neuralgia
involves 2 trigeminal divisions, they should be con-
tiguous; a combination of the maxillary and mandib-
ular divisions is most frequent. TN in the ophthalmic
division or the tongue tends to be considered an indi-
cation of TN secondary to a major neurologic disease.
However, this interpretation has not been adequately
scrutinized.4,5 It is further important to note that both
the affected division of the trigeminal nerve and the
side of the face may change over the course of the
disease.6–8
Pain qualifying as possible TN must have a parox-
ysmal character. Abrupt onset and termination of
each paroxysm are unmistakable, whereas the actual
description of the paroxysms may vary. Typical
characterizations include notions of brief, sudden,
stabbing, electric shock–like, and severe pain attacks.9
The paroxysms may last up to 2 minutes, but their
duration is usually limited to a few seconds. Fre-
quency of the pain attacks may range from 1 to over
50 a day.10,11 Refuting earlier assumptions,7 a recent
study in 200 patients with classical TN did not find
evidence supporting an increase in frequency or dura-
tion of the pain paroxysms with the disease dura-
tion.12 Unlike other forms of neuropathic pain, TN
enters into periods of complete remission in up to
63% of patients.11 These periods may last from weeks
to years.11,13
Painful symptoms associated with TN are virtually
always unilateral. Bilateral TN is very rare except for
TN caused by multiple sclerosis (MS). Occasional re-
ports of bilateral classical TN reflect successive epi-
sodes of unilateral pain switching the side of the
face rather than pain occurring simultaneously on
both sides.14,15 A meta-analysis did not reveal any
report of truly bilateral TN in 234 patients with clas-
sical TN.4 We reviewed studies of MS associated with
TN and identified 5 reports describing 24 out of 252
patients (;10%) with bilateral TN.16–20
Previous definitions of TN emphasized a stereo-
typic character of the pain. Stereotypy, however, is
not a unique feature of TN. A uniform pain character
occurs in other conditions of neuropathic and non-
neuropathic pain and should not be considered
a defining diagnostic criterion. In addition, it is not
uncommon for TN to change its sensory quality over
the course of the disease.6–8
Clinically established TN. While pain paroxysms may
occur spontaneously, patients with exclusively spon-
taneous attacks are virtually unknown. In the few
studies that examined trigger stimuli or maneuvers
in classical TN, evoked pain was reported in 99%
of the patients.11,21–23 Therefore we propose that trig-
gered pain qualifies as criterion supporting the diag-
nosis of clinically established TN (figure 1). The rare
patients without triggered attacks would remain at the
level of possible TN.
Stimulus-evoked pain is one of the most striking
features of TN, with high diagnostic value.24 In most
patients, pain is triggered by innocuous mechanical
stimuli within the trigeminal territory, including the
oral cavity. Subtlety of the trigger maneuvers is
another unique sign of TN. The stimulus may simply
be light touch or a whiff of air. More complex ma-
neuvers involve both tactile stimuli and facial move-
ment, e.g., shaving, application of makeup, brushing
teeth, eating, or drinking. Movement alone, e.g.,
smiling or talking, may suffice to provoke a pain
attack. The location of the evoked pain may differ
from the site of the stimulation and the pain can be
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felt as radiating. Stimulus-evoked pain is usually
reported by the patient. It may also be tested by
the examiner, who should pay attention to the typical
tic, an involuntary facial movement in reaction to
the pain.
The triggered pain paroxysms of TN resemble
allodynia in other conditions of neuropathic pain,
but there are important differences. The term allody-
nia was originally coined to describe the abnormal
painful response to gentle stroking of the skin in
Figure 1 New classification and diagnostic grading system for trigeminal neuralgia (TN)
aTN is typically a unilateral condition. Few patients develop TN on both sides of the face over the course of a disease, e.g., in
multiple sclerosis, but they virtually never present with simultaneous bilateral pain. bThe pain strictly follows the distribution
of the trigeminal nerve branches. It does not extend to the posterior third of the scalp, the posterior part of the external ear,
or the angle of the mandible (figure 2). cParoxysmal pain is the main complaint, but it may be accompanied by continuous
pain. dTrigger maneuvers include innocuous mechanical stimuli, facial or oral movements, or complex activities such as
shaving or applying make-up. Confined trigger zones and a common combination with brisk muscle contractions (tics) help
distinguish triggered TN from allodynia in other conditions of neuropathic pain. Trigger maneuvers may be tested by the
examiner. eMRI readily identifies major neurologic diseases, such as tumors of the cerebellopontine angle or multiple
sclerosis. Other investigations may include the neurophysiologic recording of trigeminal reflexes and trigeminal evoked
potentials, which become necessary in patients who cannot undergo MRI. fAdvanced MRI techniques are capable of dem-
onstrating neurovascular compression with morphologic changes of the trigeminal nerve root.
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postherpetic neuralgia.25 TN is also often elicited by
normally painless mechanical stimuli, or a combina-
tion of external stimuli and orofacial movements. But
unlike allodynia, trigger zones and pain sensation may
be dissociated, a phenomenon that has been inter-
preted as a sign of cross-excitation between somato-
sensory afferents.26,27 A refractory period of several
seconds or minutes during which a second pain par-
oxysm cannot be provoked is another specific feature
of TN; refractory periods do not occur with any
forms of mechanical allodynia.28 The TN trigger
zones are most often found in the central portion of
the face, around nose and mouth, such as the nasola-
bial fold, and in most patients, trigger zones are small,
even punctate.29 These phenotypic differences clearly
distinguish triggered pain in TN. Because triggered
pain paroxysms are such a unique somatosensory phe-
nomenon, they provide evidence of probable neuro-
pathic pain (figure 1).
Few authors suggest that sensory deficits are
detectable on bedside examination of patients with
classical TN,11 and absence of a sensory deficit is
one criterion for the diagnosis of classical TN in the
International Classification of Headache Disorders–
3-beta.2 However, subtle sensory abnormalities are
often found upon quantitative sensory testing.21,30
Clinical deficits of discriminatory sensory functions
are highly suspicious of TN caused by a major
underlying disease. They occurred in 25 out of 67
patients (37%) with TN secondary to tumors or
MS.4 Consequently, if sensory deficits are found dur-
ing a routine clinical examination, they should always
be followed up with additional investigations under
the assumption of secondary TN. It is important to
note that the reverse conclusion is not true: absence of
a sensory deficit does not rule out secondary TN.
The diagnosis of clinically established TN should
prompt treatment implementation and allow enroll-
ment of a patient into a clinical trial. Additional infor-
mation about the underlying etiology and definite
evidence of neuropathic pain may be preferred for
pathophysiologic studies.
Does treatment response support the diagnosis of TN?
Frequency-dependent sodium channel blockers that
increase the refractory period of action potentials are cur-
rently the most effective treatment of TN.31,32 Carbama-
zepine and oxcarbazepine, the first-line recommended
medications in many clinical guidelines, reduce pain in
approximately 90% of patients.4,5 A positive response to
these drugs, possibly as a single application of a small
dose, might therefore be regarded an operant criterion of
TN. However, no standardized criteria or generally
accepted rules exist for the definition of satisfactory
pain relief (e.g., complete vs partial suppression of pain
paroxysms). In addition, it would not be possible to
apply a treatment-related criterion to those patients
who do not tolerate the side effects of carbamazepine
or oxcarbazepine. Therefore, we decided against the
inclusion of treatment response as diagnostic criterion
of TN.
Etiologically established TN. This level of diagnostic
certainty, based on identification of a cause for the
TN, corresponds to 2 categories: classical and second-
ary TN are defined by an underlying cause. Both
diagnostic entities qualify as definite neuropathic
pain.2 However, in a relatively small proportion of
patients with clinically established TN, even the most
advanced diagnostic investigations fail to show
a cause.33–35 This condition is categorized as idio-
pathic TN (figure 1).
Classical TN. Classical TN is defined as a specific cat-
egory of TN in which MRI demonstrates vascular
compression with morphologic changes of the trigem-
inal nerve root (figure 3). Because of its sensitivity to
detect pathologic processes involving brainstem and
cranial nerves running through the base of the skull,
MRI is widely seen as the method of choice to exam-
ine the trigeminal nerve and root. MRI may reveal
neurovascular contact of the trigeminal nerve root,
but the frequency of blood vessel contact with asymp-
tomatic trigeminal nerve roots cautions against the
implementation of contact alone as a diagnostic
Figure 2 Innervation territories of the trigeminal nerve
Facial and intraoral territories of innervation of the 3 trigeminal branches (ophthalmic, max-
illary, and mandibular). The white areas are innervated by cervical nerves. The light gray
areas in the back of tongue and throat are innervated by the glossopharyngeal nerve.
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criterion. In a recent meta-analysis of 9 high-quality
blinded and controlled studies, neurovascular contact
was found in 471 out of 531 symptomatic nerves
(89%) and 244 of 681 asymptomatic nerves (36%),
indicating high sensitivity but poor specificity.35 Several
authors have instead emphasized the importance of
physical impact of the blood vessel on the nerve.36,37
Nerve dislocation or atrophy raised the specificity to
97%. Two prospective studies have corroborated these
results.38,39 Location of the neurovascular contact also
appears to be relevant. Compression of the trigeminal
nerve root at its entry into the brainstem increased
specificity and positive predictive value to 100%,
with high interobserver consistency.35 The degree of
morphologic root changes is therapeutically relevant.
Long-term outcome after surgical revision of mere
neurovascular contact is uncertain compared to the
decompression of dislocated, distorted, or flattened
nerve roots.37,40,41 Flattening and atrophy appear to be
particularly sensitive signs of clinically relevant
compression.36,41 Advanced MRI techniques further
allow for visualization of structural changes within
the root that are highly suggestive of physical
alteration and provide high predictive value for pain
relief after decompression.38 However, it is important
to acknowledge that all cited studies relied on
a clinical diagnosis of TN before MRI. MRI is
a valuable diagnostic tool only if preceded by an
evaluation of symptoms and signs that indicate
probable TN.
Reliable detection of neurovascular compression re-
quires the use of specific imaging techniques with 3D
reconstruction. Several methods improve the depiction
of the trigeminal nerve root and adjacent blood vessels
in the posterior fossa. Typical imaging paradigms
include sequences for 3D T2-weighted MRI, e.g.,
driven equilibrium or constructive interference in
steady state, for a detailed examination of cisternal
and cavernous nerve segments (figure 3), 3D time-
of-flight magnetic resonance angiography for the visu-
alization of arteries, and 3D T1-weighted MRI with
gadolinium or phase-contrast MRI for the visualization
of veins.33,38,42 Diffusion tensor imaging (DTI) and
fiber tractography detect abnormalities of the trigemi-
nal nerve root that normalize following decompression
or radiosurgery.43,44 DTI may become an essential
diagnostic test for TN in the near future. However,
so far too few studies have been conducted with suffi-
cient stringency to derive diagnostic criteria with sen-
sitivity/specificity. Most investigations involved group
analyses only, and some yielded conflicting results.
Pending additional evaluation, these imaging tools
may in the future allow predicting the outcome of
neurosurgical treatment.44
Secondary TN. Diagnosis of secondary TN relies on
the demonstration of a major neurologic disease that
causes the neuralgia. A tumor at the cerebellopontine
angle or MS causes TN in 15% of patients.4,5 Tumors
leading to TN are mostly benign and typically
Figure 3 Neurovascular compression of the
trigeminal root
3D constructive interference in steady state MRI shows
axial sections at the level of trigeminal nerve root entry into
the pons. (A) Bilateral neurovascular contact without mor-
phologic changes of the root in a patient with left trigeminal
neuralgia (TN). Nerve (long arrows) and blood vessel (short
arrows) appear hypointense surrounded by hyperintense
CSF. Contact is seen at the root entry zone as well as
mid-cisternal segment. (B, C) Morphologic changes exceed-
ing mere neurovascular contact of the trigeminal nerve root
are compatible with the diagnosis of classical TN. (B) Root
atrophy in a patient with right TN. (C) Indentation and dislo-
cation of the root in a patient with right TN (short arrow).
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compress the root near its entry into the pons. The
compression induces focal demyelination and is
thought to trigger paroxysmal ectopic discharges.
Malignant tumors are more likely to infiltrate the nerve
and lead to axonal degeneration. If malignant tumors
cause trigeminal pain, it usually does not resemble the
pain attacks experienced in TN. TN occurs in 2%–5%
of patients with MS; conversely, MS is detected in
2%–14% of patients with TN.45,46 The development
of pain paroxysms has variably been explained with the
presence of demyelinating plaques in the pons or
increased susceptibility of the trigeminal nerve root
to neurovascular compression.46–50
While MRI is the most useful investigation in the
search of underlying etiology, imaging is not possible
in some cases, e.g., patients with metal implants such
as cardiac pacemakers. Recording of the trigeminal re-
flexes is an established alternative assessment of trigem-
inal nerve function.51 The reflexes can be elicited from
all branches of the trigeminal nerve. Reflex abnormal-
ities achieve a sensitivity of 94% and specificity of 87%
to identify secondary TN, comparable to the diagnos-
tic accuracy of MRI.4,5 Trigeminal reflex recording is
particularly helpful in rare cases of TN secondary to
neuropathy (appendix e-2). Various evoked potentials
after electrical or thermal stimuli have been studied in
TN. In contrast to the trigeminal reflexes, evoked po-
tentials may be altered even in idiopathic or classical
TN: we found them abnormal in 103 out of 209
patients, thus yielding a sensitivity of 50% (appendix
e-2). However, their specificity in revealing secondary
TN (64%) is low.5,52,53
TN with continuous pain. Some patients with TN expe-
rience pain between attacks. This pain is continuous or
near-continuous and qualitatively different from the
paroxysmal pain. It is not associated with any other
cause for facial pain. Common descriptions include
dull, burning, or tingling. Its distribution coincides
with that of the paroxysmal pain, and fluctuations
in intensity as well as periods of remission and
recurrence parallel those of the paroxysmal pain, thus
demonstrating a close relationship between the
two.11,54,55 It is known by several designations,
including atypical TN and TN type 2 (appendix e-1),
but we prefer the term TN with continuous pain,
because it directly highlights the defining feature, is
easy to communicate, and is least prone to
misinterpretation.
Occasionally patients with severe TN may
describe their paroxysms as continuous pain, so that
differentiating the exact characteristics of their pain
becomes difficult. If movement is one of the pain-
triggering factors, pain may be suppressed when pa-
tients hold completely still for a few minutes, allowing
for a better distinction of pain features that match the
defining criteria of TN.56
Continuous pain is not related to etiology. It oc-
curs in idiopathic, classical, or secondary TN.
Whether the continuity of pain results from progres-
sive root damage or a secondary central mechanism is
unclear.53,55 Several authors have suggested that con-
tinuous pain is associated with poorer outcome after
surgical intervention,6,37,57,58 but this conclusion is
controversial.41 There is, however, compelling evi-
dence that continuous and paroxysmal pain may
improve independently after microvascular decom-
pression, suggesting that the mechanisms responsible
for the 2 pain components are distinct.8,36,58
DISCUSSION We have developed a new definition
and diagnostic classification for TN (table), one that
integrates an evaluation of diagnostic certainty based
on criteria equivalent to those applied for neuropathic
pain in general.2 The added assessment of diagnostic
certainty will be helpful for treatment decisions.
Diagnostic requirements for idiopathic, classical,
and secondary TN are based on a thorough review
of clinical and etiologic features of TN.
Even after MRI or other investigation, the etiology
of TN remains unclear (idiopathic) in approximately
11% of patients.33–35 Classical TN, caused by neuro-
vascular compression, is the most frequent form of TN
with defined etiology. Morphologic changes indicative
of compression rather thanmere vascular contact of the
trigeminal root markedly increase the specificity of the
diagnosis. Therapeutic relevance of these stricter crite-
ria is supported by improved outcome of microvascular
surgery in patients with clear signs of morphologic root
alterations.35 MRI is the investigation of choice to
detect trigeminal nerve compression. 3D reconstruc-
tions delineate the anatomic setting with high levels
of sensitivity and specificity that help avoid unnecessary
posterior fossa exploration. In about 15% of patients
with TN, MRI reveals a major neurologic disease such
as a benign tumor or MS.4 Secondary TN is a well-
established term for the designation of these manifes-
tations of neuralgia and should be maintained.
Table Definition and classification of trigeminal neuralgia (TN)
Definition TN is orofacial pain restricted to one or more divisions of the trigeminal nerve.
With the exception of TN caused by multiple sclerosis, the pain affects one side
of the face. It is abrupt in onset and typically lasts only a few seconds (2 minutes
at maximum). Patients may report their pain as arising spontaneously but these
pain paroxysms can always be triggered by innocuous mechanical stimuli or
movements.
Patients usually do not experience pain between paroxysms. If they do report
additional continuous pain, in the same distribution and in the same periods as
the paroxysmal pain, they are considered to have TN with continuous pain.
Classification TN is classified in 3 etiologic categories. Idiopathic TN occurs without apparent
cause. Classical TN is caused by vascular compression of the trigeminal nerve
root. Secondary TN is the consequence of a major neurologic disease, e.g.,
a tumor of the cerebellopontine angle or multiple sclerosis.
Either phenotype (with purely paroxysmal pain or with additional continuous
pain) may occur with any of the 3 categories.
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The diagnostic grading system of neuropathic pain
is difficult to administer in TN, because it emphasizes
the value of pathologic findings, which are absent in
idiopathic TN. However, patient description of trig-
ger zones or demonstration of trigger maneuvers
in the physical examination is sufficiently specific
to clinically establish TN and diagnose probable neu-
ropathic pain. Additional investigations, primarily
MRI, that reveal the etiology of classical or secondary
TN fulfill the requirements for a diagnosis of definite
neuropathic pain.2
Evaluation and treatment of TN regularly involve
clinicians in diverse fields of medicine, including neu-
rology, neuroradiology, neurosurgery, dentistry, max-
illofacial surgery, and specialists in pain medicine. A
classification system for TN must account for com-
mon differential diagnoses in these disciplines. The
likelihood that patients with classical TN, whose pain
is insufficiently relieved by medication, or patients
with secondary TN will require invasive treatment
highlights the importance of diagnostic certainty.
The ICHD does not differentiate levels of evidence
and in its most recent edition3 dismisses the widely
accepted diagnostic label of secondary TN. Instead,
ICHD-3 favors painful trigeminal neuropathy as
a diagnostic label for TN that is caused by a major
neurologic disease. However, this category also in-
cludes conditions that are distinct from TN and pres-
ent with different pain phenotypes; for example,
trigeminal pain caused by acute herpes zoster. Sec-
ondary TN is a well-established and widely accepted
designation that should be maintained to avoid
confusion.
The proposed new classification provides defined
criteria that offer diagnostic accuracy with the added
value of a grading system for neuropathic pain
(appendix e-3). The classification is designed for intu-
itive implementation in diagnostic decisions and
treatment guidelines. We encourage clinicians and
academics to begin using the classification, which will
be reflected in the upcoming revision of the WHO’s
ICD.59,60
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